Emcure Pharmaceuticals Ltd
NSE: EMCURE | BSE: 544210
₹1,731.20
₹-13.40
(-0.77%)
As on 10-Jun-2026IST
Market cap
₹32,857 Cr
Revenue (TTM)
₹9,204 Cr
P/E Ratio
35.5
P/B Ratio
6.6
Div. Yield
0.2 %
Quality Score
5/10
Growth Score
6/10
Valuation Score
4/10
Momentum Score
9/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹924 Cr
-
ROE
19.2 %
-
ROCE
22.5 %
-
Industry P/E
46.12
-
EV/EBITDA
18.1
-
Debt to Equity
0.1
-
Book Value
₹261
-
EPS
₹50
-
Face value
10
-
Shares outstanding
189,659,547
10 Years Aggregate
CFO
₹6,491.08 Cr
EBITDA
₹10,649.27 Cr
Net Profit
₹4,222.35 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Emcure Pharmaceuticals
| 26.9 | 5.4 | 13.8 | 30.6 | -- | -- | -- |
|
BSE Healthcare
| 8.2 | 1.0 | 8.3 | 8.0 | 24.8 | 13.5 | 12.1 |
|
Company
|
2025
|
|---|---|
|
Emcure Pharmaceuticals
| -6.6 |
|
BSE Small Cap
| -6.6 |
|
BSE Healthcare
| -3.3 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Emcure Pharmaceuticals
|
1,731.2 | 32,856.6 | 9,203.5 | 941.3 | 15.4 | 19.6 | 35.5 | 6.6 |
| 1,031.4 | 12,756.9 | 2,551.8 | 564.5 | 28.3 | 18.4 | 22.6 | 3.8 | |
| 469.8 | 8,153.7 | 947.3 | 247.8 | 28.5 | 18.9 | 32.9 | 6.0 | |
| 1,330.7 | 13,785.3 | 1,054.9 | 256.3 | 27.8 | 13.7 | 52.8 | 6.8 | |
| 384.1 | 4,240.9 | 165.8 | 46.7 | 37.8 | 16.9 | 90.8 | 14.7 | |
| 129.5 | 3,798.3 | 2,319.1 | 137.6 | 8.1 | 8.2 | 27.6 | 2.1 | |
| 16,946.0 | 21,765.5 | 2,023.0 | 364.0 | 23.9 | 20.8 | 59.8 | 11.6 | |
| 851.0 | 4,309.1 | 811.3 | 21.0 | 0.7 | 2.1 | 209.7 | 3.3 | |
| 1,112.6 | 5,103.7 | 649.5 | 121.6 | 23.7 | 13.2 | 44.2 | 5.5 | |
| 268.8 | 7,040.0 | 7.1 | -276.3 | -4,077.5 | -63.3 | -- | 11.9 |
Shareholding Pattern
View DetailsNews & Analysis
All News
5 min read•By Hemkesh Khattar
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology,... respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India. Read more
-
Incorporated
1981
-
Chairman
Berjis Desai
-
Managing Director
Satish Mehta
-
Headquarters
Pune, Maharashtra
-
Website
Looking for more details about Emcure Pharmaceuticals Ltd’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Emcure Pharmaceuticals
What is the current share price of Emcure Pharmaceuticals Ltd Today?
The share price of Emcure Pharmaceuticals Ltd is ₹1,731.20 (NSE) and ₹1,729.90 (BSE) as of 10-Jun-2026 IST. Emcure Pharmaceuticals Ltd has given a return of 30.57% in the last 1 years.
What is the current PB & PE ratio of Emcure Pharmaceuticals Ltd?
The P/E ratio of Emcure Pharmaceuticals Ltd is 35.55 times as on 10-Jun-2026, a 23 discount to its peers’ median range of 46.12 times.
The P/B ratio of Emcure Pharmaceuticals Ltd is 6.64 times as on 10-Jun-2026, a 96 premium to its peers’ median range of 3.38 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
29.84
|
4.58
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
What is the 52 Week High and Low of Emcure Pharmaceuticals Ltd?
The 52-week high and low of Emcure Pharmaceuticals Ltd are Rs 1,830.00 and Rs 1,228.90 as of 10-Jun-2026.
What is the market cap of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd has a market capitalisation of ₹ 32,857 Cr as on 10-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Emcure Pharmaceuticals Ltd?
Before investing in Emcure Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.